hotspot -WSS

hotspot

author：leisure time 2025-10-02 11:10:17 - browse：47544

In a surprise move, the Food and Drug Administration has called for a meeting of outside advisers to discuss whether an Alzheimer’s drug from Eli Lilly should be approved, even as many outsiders expected the medicine to receive regulatory clearance this month.

The drug, donanemab, succeeded in its Phase 3 trial, resulting in a 35% slowing of Alzheimer’s disease progression versus placebo. But Lilly on Friday said that the FDA expects to call a meeting of an advisory committee to review the trial, saying that the agency had told the company “it wants to further understand topics related to evaluating the safety and efficacy of donanemab, including the safety results in donanemab-treated patients and the efficacy implications of the unique trial design” of the study.

A date for the meeting has not been set yet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： FDA panel gives mixed vote on blood pressure devices

hotspot

WSS

Radiation, mainstay of cancer treatment, begins a fade

Mitch McConnell episode has important public health takeaway

AstraZeneca challenges Medicare drug negotiation program

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

AstraZeneca bets AAV gene therapy will still deliver the goods

Study finds new variant for Parkinson’s in African populations

explore

hotspot

Wikipedia

23andMe had bad news about my health. I wish a person had delivered it

How a symptom of dementia informs our understanding of creativity

New air purifier tech could be key to improving indoor air quality

Vertex non

Moonlake's readout produced a cash windfall. Risks remain

5 important ways Henrietta Lacks changed medical science

Hepatitis C has a cure — but many Americans still lack access to it

Australia’s approach to dialysis celebrates life

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Scientists inch closer to single

hotspot

Radiation, mainstay of cancer treatment, begins a fade

What AAP's gender

Appeals court upholds limits to abortion pill

Diversity in medical illustrations gets boost from Chidiebere Ibe

Winners, losers from Medicare’s list of drugs subject to price talks

Apellis safety probe of eye disease drug centers on injection needle

focus

hotspot

explore

explore